Today: 20 May 2026
Browse Category

LSE:GSK 9 December 2025 - 27 December 2025

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

London Stock Exchange Update: FTSE 100 Near Record Highs After a Strong 2025 — What to Watch When Trading Reopens

The London Stock Exchange remains closed for the weekend and will reopen at 8:00 a.m. London time on Monday, December 29. The FTSE 100 ended the Christmas Eve half-day at 9,870.68, down 0.2%. The index is on track for a 20.7% annual gain, outperforming the S&P 500. The Bank of England cut its policy rate to 3.75% in December.
27 December 2025
···
GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK plc Stock (NYSE: GSK, LSE: GSK): Latest News, Forecasts, and Key Catalysts as of Dec. 26, 2025

GSK’s U.S. ADR closed at $48.96 after the FDA approved its twice-yearly asthma drug Exdensur, but withheld approval for a related use. The company also reached a U.S. drug-pricing deal affecting its respiratory products and reported progress on vaccine expansion in Europe. London trading paused for holidays. Shingrix faces new competition.
26 December 2025
···
UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

UK Stock Market Today: FTSE 100 Pauses for Boxing Day as Investors Weigh Retail Signals, Precious-Metals Surge and 2026 Outlook (26 December 2025)

The London Stock Exchange is closed Friday for Boxing Day, halting UK trading after a shortened Christmas Eve session where the FTSE 100 slipped 0.2%. Investors are watching global moves and a spike in precious metals, which could impact London-listed miners when trading resumes. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion. The FTSE 100 is on track for a roughly 21% gain in 2025.
26 December 2025
·····
UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

UK Stock Market Preview for 26 December 2025: Boxing Day Closure, FTSE 100 Drivers, Sterling Moves, Oil Pressure and the BoE Outlook

The London Stock Exchange will be closed on Friday, 26 December 2025, for Boxing Day. In the last session before the break, the FTSE 100 fell 0.2%. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion, valuing Castrol at $10.1 billion. UK traders will return after the holiday to a market influenced by global moves and BP’s deal.
25 December 2025
····
United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

United Kingdom Stock Market Today: FTSE 100 Holiday Pause, BP Castrol Deal and 2026 Outlook (25 Dec 2025)

The London Stock Exchange is closed for Christmas and Boxing Day, with trading set to resume after the long weekend. The FTSE 100 slipped 0.2% in a quiet half-day session on Christmas Eve. BP agreed to sell a 65% stake in Castrol to Stonepeak for about $6 billion, valuing Castrol at $10.1 billion. The Bank of England recently cut rates to 3.75%.
25 December 2025
····
GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK plc Stock News and Forecast (Dec. 20, 2025): TrumpRx Pricing Deal, Exdensur FDA Approval, Buybacks, and Analyst Targets

GSK agreed to a U.S. drug-pricing deal covering its respiratory portfolio, securing a three-year exemption from tariffs and pledging lower Medicaid prices and direct-to-consumer discounts. The company also received fresh FDA approval for a severe asthma drug and expanded vaccine indications in Europe. GSK’s ADR closed Friday, Dec. 19, at $48.61.
20 December 2025
···
GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK Stock News Today (Dec. 18, 2025): Buyback Update, New FDA Approvals, and Analyst Forecasts for GSK plc

GSK said Thursday it bought 235,000 shares on Dec. 17 as part of its ongoing buyback, bringing total repurchases since Sept. 30 to over 14 million shares. GSK’s ADR traded at $48.71 in New York, down 0.13%. The company reported 239.6 million shares now held in treasury. Earlier this week, the FDA approved GSK’s Exdensur for severe asthma.
18 December 2025
··
GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

GSK Stock News Today (Dec. 17, 2025): FDA Approves Twice‑Yearly Asthma Drug Exdensur as Analysts Reassess GSK plc’s 2026 Outlook

The FDA approved GSK’s Exdensur (depemokimab-ulaa) on Dec. 17 as a twice-yearly add-on treatment for severe eosinophilic asthma in patients 12 and older. Phase III trials showed up to 58% fewer annual asthma exacerbations versus placebo. The FDA declined approval for a second indication, chronic rhinosinusitis with nasal polyps. GSK faces a leadership change Jan. 1, 2026.
17 December 2025
··
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms

GSK shares closed at 1,833.50p in London on Dec. 15, up 0.49%, with the US ADR trading near $49.24. The UK approved Exdensur (depemokimab), the first twice-yearly asthma biologic, for asthma and chronic rhinosinusitis with nasal polyps. European and US regulators also advanced GSK’s respiratory and vaccine programs. GSK’s stock is up nearly 38% over the past year.
16 December 2025
··
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead

GSK faces a key FDA decision on depemokimab for severe asthma and nasal polyps on Dec. 16, following recent EU regulatory backing for the drug and other respiratory products. GSK ADRs last traded at $48.81, while London shares opened at 1,816.50p. Analysts are watching for potential shifts in revenue forecasts and valuation as regulatory outcomes approach.
15 December 2025
··
GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK closed at 1,824.5p in London on Dec. 12, up about 1% for the week, despite a 2% drop on Dec. 9. The company secured three positive CHMP opinions in Europe, including for depemokimab in severe asthma and Arexvy’s expanded use in adults 18+. GSK’s U.S. ADR last traded at $48.81. EU decisions on these products are expected in early 2026.
14 December 2025
···
GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK Stock News Today (Dec. 12, 2025): Arexvy EU Expansion, Blujepa FDA Approval, Analyst Forecasts and What’s Next

GSK shares traded near $48.88 Friday as the company reported key regulatory wins. The EMA’s CHMP backed expanding Arexvy’s RSV vaccine to all adults 18+ in Europe, with a final decision expected in February. The FDA also approved Blujepa (gepotidacin) for gonorrhea, marking the first new antibiotic class for the infection in decades. Analyst consensus sees Arexvy sales rising to £1.17 billion by 2031.
12 December 2025
··
GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK’s Emma Walmsley Hails US as ‘Best Place to Invest’ as UK Pharma Faces Tariffs, Rebate Cuts and a Fight for Jobs

GSK chief executive Emma Walmsley said the US is now the top destination for pharmaceutical investment, warning Britain risks falling further behind. Walmsley cited the US and China as key growth markets and confirmed GSK will invest $30 billion in the US by 2030. Her comments follow similar moves by AstraZeneca and recent UK government efforts to retain drug industry investment.
11 December 2025
··
GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.
10 December 2025
···
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.
9 December 2025
···
1 2 3 4

Stock Market Today

  • Stocks Added to Zacks Strong Sell List on May 20th: BRCC, CVE, MITT
    May 20, 2026, 5:27 AM EDT. Three stocks joined the Zacks Rank #5 (Strong Sell) list on May 20th. BRC Inc. (BRCC), a coffee and apparel seller, saw its current year earnings estimate cut by 33.3%. Cenovus Energy Inc. (CVE), an oil and gas producer, had its earnings forecast lowered by 24.5%. AG Mortgage Investment Trust (MITT), a residential mortgage REIT, faced a 17.5% earnings revision downward. These revisions reflect growing bearish sentiment as analysts adjust expectations. The Zacks Rank #5 indicates a strong sell recommendation based on recent downward earnings revisions over 60 days.

Latest articles

Intel’s AI Comeback Just Got a $150 Wall Street Test

Intel’s AI Comeback Just Got a $150 Wall Street Test

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Marvell shares active as earnings approach, AI chip focus in view

Marvell shares active as earnings approach, AI chip focus in view

20 May 2026
Marvell Technology shares rose 4.53% to $184.25 in premarket trading Wednesday, extending Tuesday’s 4.35% gain. The company will report fiscal Q1 2027 results after the close on May 27. Analysts at Evercore ISI, Melius Research, and CLSA raised price targets, citing strong demand for custom AI chips. Marvell posted record fiscal 2026 revenue of $8.195 billion in March.
SpaceX restarts Starlink launches after satellite mishap — and another Falcon 9 is already queued

SpaceX IPO Moves Closer as Goldman Nears Top Role in $1.75 Trillion Listing

20 May 2026
Goldman Sachs is set to lead SpaceX’s planned IPO, which could become the largest in history, with a targeted valuation of about $1.75 trillion, Reuters reported. SpaceX aims to publish its prospectus as soon as Wednesday and list on Nasdaq under the ticker SPCX as early as June 12. The company’s next Starship test flight is scheduled for May 21 from Texas. Morgan Stanley, Bank of America, Citigroup, and JPMorgan are also expected to play major roles.
Go toTop